Is bivi a good buy

BioVie (BIVI) appears to be a good buy based on several indicators and recent developments:

1. Analyst Ratings and Price Targets: The consensus among analysts is a "Strong Buy" rating, with an average price target of $3. This suggests that analysts are optimistic about the stock's future performance and believe it has room to grow from its current price.

2. Technical Indicators: The Relative Strength Index (RSI) is at 42.19, which is neither overbought nor oversold, suggesting that the stock is neither overextended nor lacking in momentum. The Moving Average Convergence Divergence (MACD) is at 0.05, which could indicate bullish momentum.

3. Support and Resistance Levels: The stock does not have a defined support or resistance level, which could indicate a lack of investor interest or uncertainty about the stock's future direction.
4. Moving Averages: The 5-day moving average is $2.85, and the 10-day moving average is $2.93, both of which are below the current trading price. However, the 50-day moving average is $3.21, which is above the current trading price, suggesting that the stock has been trending upwards recently.

5. Financial Ratios: The company's P/E ratio is -0.45, which indicates that the company is not currently profitable, but this is not necessarily a concern as the company is in the development stage and may not yet be generating revenue. The P/S ratio is not available, and the P/B ratio is 0.9, which suggests that the stock may be undervalued based on its assets.

6. Recent Developments: The company has recently priced a public offering, which could provide additional capital for development and growth. Additionally, the company has received all necessary scientific approvals for a $12.6 million grant to initiate a Phase 2 trial of bezisterim for long COVID, which could be a positive catalyst for the stock.
7. Market Sentiment: There have been no recent negative developments or news that would suggest a bearish outlook for the stock.

In conclusion, the "Strong Buy" rating from analysts, the average price target above the current trading price, and the recent positive developments suggest that BioVie is a good buy at this time. However, investors should consider the high risks associated with penny stocks and the company's current lack of profitability.